Adoptive cell transfer therapy 'less effective' in pretreated metastatic melanoma
US researchers suggest that lymphocytes should be harvested before embarking on immunotherapy
Patients with metastatic melanoma that have relapsed following immunotherapy may not respond as well to adoptive cell transfer of tumour-infiltrating lymphocytes (ACT-TIL) as those who have never received these treatments, a study shows.
With ACT-TIL, autologous tumour-infiltrating lymphocytes are taken from a patient's tumour, grown in the laboratory, and then given back to the patient to help attack cancer cells.
Tumours exposed to prior treatments, including newer immunotherapies and targeted therapies, may yield fewer or
